Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will present at the following upcoming investor and scientific conferences.

IBC's 17 th Annual TIDES Conference - San Diego, May 3-6, 2015

May 5, 4:45 p.m. PDT - Christine Wooddell, Ph.D., group leader will deliver an oral presentation titled, " A Hepatocyte-Targeted RNAi Therapeutic for Alpha-1-Antitrypsin Deficiency-Associated Liver Disease"

May 6, 12:15 p.m. PDT - David Lewis, Ph.D., chief scientific officer will deliver an oral presentation titled, " A Targeted siRNA-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection"

Deutsche Bank 40th Annual Health Care Conference - Boston, May 6-7, 2015

May 7, 2:50 p.m. EDT - Bruce Given, M.D., chief operating officer will make a corporate presentation

A live webcast of the presentation from the Deutsche Bank conference can be accessed by visiting the Events section of the company's website at A replay will also be archived on the website.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus and ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency.

For more information please visit, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, actions of the U.S. Food and Drug Administration (FDA) and similar global regulatory bodies, rapid technological change in our markets, challenges to the validity of our intellectual property rights, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Research Corporation

Copyright Business Wire 2010